分子靶向药物在肾癌治疗中的合理应用
摘要
肾癌是泌尿系统常见恶性肿瘤之一.随着对肾癌发病机制的不断研究,美国FDA已批准了7种分子靶向药物用于晚期肾癌的治疗,成为除外科手术外最重要的治疗手段.本文主要探讨分子靶向药物在晚期肾癌、新辅助治疗、术后辅助治疗、序贯用药、联合用药、非透明细胞肾癌中的合理应用及临床进展.
出处
《国际泌尿系统杂志》
2015年第2期289-292,共4页
International Journal of Urology and Nephrology
参考文献32
-
1Kane CJ,Mallin K, Ritchey J, et al. Renal cell cancer stage migra- tion [ J ]. Cancer,2008,113 ( 1 ) :78 - 83.
-
2Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up [ J ]. Annals of Oncology ,2012,23 ( suppl 7 ) : 65 - 71.
-
3Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States[ J]. Jama, 1999,281 ( 17 ) :1628 - 1631.
-
4. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high - dose bolus in- terleukin - 2 for patients with high - risk renal cell carcinoma : a cytokine working group randomized trial [ J ]. Journal of Clinical Oncology, 2003,21 ( 16 ) : 3133 - 3140.
-
5Karam JA, Devine CE, Urbauer DL, et al. Phase 2 Trial of Neoadju- vant Axitinib in Patients with Locally Advanced Nomnetastatic Clear Cell Renal Cell Carcinmna[J ]. European urology,2014.
-
6Powles T, Kayani I, Blank C, et at. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer[ J]. Annals of Oncology,2011,22 (5) : 1041 - 1047.
-
7Abel E J, Culp SH, Tannir NM, et at. Primary tmnor response to tar- geted agents in patients with metastatic renal cell carcinoma [ J ], European m'ology,2011,59( 1 ) : 10 - 15.
-
8Silberstein JL, Millard F, Mehrazin R, et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron -paring surgery [ J ]. BJU international ,2010,106 ( 9 ) : 1270 - 1276.
-
9Hellenthal NJ, Underwood W, Penetrante R, et at. Prospective clini- cal trial of preoperative sunitinib in patients with renal cell carcino- ma[ J]. The Journal of urology,2010,184(3 ) :859 -864.
-
10Cost NG, Delacrnix Jr SE, Sleeper JP, et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus [ J ]. European urology,2011,59 (6) :912 - 918.
-
1周正兴,梁朝朝.膀胱肿瘤的诊断学研究进展[J].国际泌尿系统杂志,2006,26(1):28-32. 被引量:4
-
2戴学军,漆松涛.颅咽管瘤的手术治疗[J].国外医学(神经病学.神经外科学分册),2001,28(1):16-18. 被引量:1
-
3赵立民,张丹.乳腺癌皮下积液危险因素及其对上肢淋巴水肿发生影响的研究[J].山西医药杂志,2017,46(7):783-785. 被引量:8
-
4刘鹏熙,唐利立.乳腺癌激素治疗研究进展[J].国外医学(生理病理科学与临床分册),2002,22(3):305-307. 被引量:5
-
5杜雪莲,王聪,刘明,郑兴,卢乡伟,盛修贵.紫杉醇加卡铂与吉西他滨为基础联合化疗序贯用药对降低上皮性卵巢癌复发的临床研究[J].中国实用妇科与产科杂志,2015,31(1):59-64. 被引量:15
-
6陈逢生,崔彦芝,罗荣城,李爱民,伍婧,张华.索拉非尼与顺铂的不同联合方案对肝癌HepG2细胞的作用研究[J].实用医学杂志,2008,24(7):1096-1098. 被引量:3
-
7王一帆,毕清,任宏轩.联合检测血清肿瘤标志物诊断非小细胞肺癌的研究进展[J].南昌大学学报(医学版),2013,53(1):76-78. 被引量:14
-
8高永良.卵巢癌腹水的腹腔内化疗(附12例疗效分析)[J].浙江医学,1990,12(2):17-19. 被引量:1
-
9方立俭,束永前,范萍,刘连科.塞来昔布联合羟基喜树碱对胃癌细胞的生长抑制作用及机制探讨[J].徐州医学院学报,2010,30(12):793-796. 被引量:1
-
10李志鹏,曾兆林.肝门胆管癌中IL-6与COX-2作用的研究进展[J].世界华人消化杂志,2014,22(22):3225-3231. 被引量:1